

Material Information (3176 MEDIGEN?????)

SEQ_NO	1	Date of announcement	2024/06/06	Time of announcement	15:36:39
Subject	Taiwan MOHW has approved a New Version of the collaborative autologous Natural Killer cell therapy project by the Company and Wanfang Hospital				
Date of events	2024/06/06	To which item it meets	paragraph 53		

Statement

1.Date of occurrence of the event:2024/06/06
2.Company name:Medigen Biotechnology Corp. (Medigen)
3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office
4.Reciprocal shareholding ratios:N/A
5.Cause of occurrence:
Medigen, in collaboration with Taipei Municipal Wanfang Hospital managed by Taipei Medical University (referred to as Wanfang Hospital), has applied to the Ministry of Health and Welfare (MOHW) on January 22, 2024, for a new version of the Autologous Natural Killer (Magicell-NK) cell therapy project for treating stage IV solid tumors in accordance with the regulations of the "Regulations Governing the Application of Specific Medical Examination Technique and Medical Device". On June 6, 2024, Medigen received the approval letter from the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP).
6.Countermeasures:The announcement was released in accordance with the approval letter of the Ministry of Health and Welfare
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
Details on the approved items in the abovementioned Wanfang Hospital cell therapy project:
(1)Type of Cell Therapy : Autologous natural killer cells (NK cells) - Magicell-NK.
(2)Indications: Stage IV solid tumors, including Brain cancer, breast cancer, lung cancer, esophageal cancer, stomach cancer, liver cancer, bile duct cancer, pancreatic cancer, prostate cancer, colorectal cancer.
(3)Cell Processing Unit: Medigen's cell processing unit
(4)Validity Period: From June 4, 2024, to February 2, 2026.